Purpose
Double-pigtail stent intolerance reduces patient’s quality of life. By decreasing the amount of material within the bladder, it should be possible to attenuate stent’s symptoms. We evaluated the tolerance of a new stent with a dedicated questionnaire.MethodsThe major innovation of the pigtail suture stent (PSS) is in the replacement of the lower part of the double-pigtail stent with a 0.3F suture. A total of 79 consecutive patients agreed to be fitted with a PSS. The double-pigtail stents of 24 patients complaining strongly of symptoms were replaced with PSS (group 1), and 55 other patients were fitted directly with the PSS after an ureteral endoscopic intervention (group 2). The questionnaire was prospectively administered to patients at baseline and Day 15 post-placement.ResultsAll questionnaires were returned. In group 1, the replacement of the double-pigtail stent with a PSS significantly decreased urinary symptom scores (35.2 ± 7.5 vs. 23.6 ± 5.4; p = 2 × 10−6) and pain scores (11.0 ± 3.9 vs. 4.9 ± 3.1; p = 1 × 10−7). In group 1, the baseline scores were not significantly different from those of control group with double-pigtail stent. In group 2, the urinary scores with PSS were significantly different from those of baseline without stent. The scores of the two groups fitted with a PSS were not significantly different at Day 15 post-placement. Unexpectedly, following PSS implantation, we observe a clear dilation of the ureter without inflammation around the suture.ConclusionsThe PSS significantly decreases stent’s symptoms and constitutes a medical advance in the domain of ureteral stent tolerance.Electronic supplementary materialThe online version of this article (doi:10.1007/s00345-014-1394-2) contains supplementary material, which is available to authorized users.
These elements should be included in future classification reassessment to efficiently determine the time for surgery in grade IV renal traumas, generally leading to nephrectomy.
A 45-year-old man with a left testis tumor with a 25 mm para-aortic lymph node swelling, multiple bilateral pulmonary metastases, bilateral pulmonary embolism, and inferior vena cava (IVC) thrombus underwent a radical orchidectomy in our institution. The thrombus extended from the left gonadal vein to the left renal vein to the IVC. The fluorine-18 fluorodeoxyglucose (f-FDG) positron emission tomography (PET) computerized tomography (CT) demonstrated a hypermetabolic focus in the retroperitoneum and in the IVC thrombus. Before orchidectomy only lactate dehydrogenase (LDH) was high but all the serum tumor markers increased postoperatively. The tumor was staged pT1N2M1aS1, which was an intermediate prognosis, based on the International Germ Cell Cancer Collaborative Group consensus (IGCCCG). After 4 courses of bleomycin, etoposide, and cisplatin (BEP) chemotherapy the patient's tumor markers normalized and the thrombus disappeared. There was only one residual retroperitoneal lymph node M1. Retroperitoneal lymph node dissection was performed. The pathological examination revealed only necrotic tissues. The patient has been disease-free since surgery.
BackgroundPercutaneous nephrolithotomy (PCNL) is recommended for treating staghorn stones or stones measuring > 20 mm. Extracorporeal shockwave lithotripsy (ESWL) or flexible ureteroscopy (URS) may be used as a complement. However, PCNL can cause trauma to the kidney parenchyma, and patients may find a noninvasive procedure, such as ESWL, to be more attractive.ObjectivesThe aim of this study was to evaluate the clinical efficiency of MiniJFil® stenting associated with ESWL or second-line URS for the treatment of medium-to-large kidney stones. The MiniJFil® is a stent reduced to a suture of 0.3F attached to a renal pigtail. The entire ureter is occupied only by the suture of the stent.MethodsWe retrospectively analyzed the data of 28 patients. Twenty-four patients had kidney stones measuring > 15 mm (group 1) and four patients had staghorn stones (group 2). All of the patients were fitted with MiniJFil® 2 - 3 weeks before any treatment. ESWL was always our first-line therapy. Stone-free (SF) status was defined as no evidence of stones.ResultsIn group 1, the mean largest and cumulative stone diameters, respectively, were 18.7 ± 5.7 mm and 45.0 ± 12.0 mm. In group 2, the mean volume was 6,288.4 ± 2,733.0 mm3. The overall SF was 96.4% (100% for group 1 and 75% for group 2). The mean number of sessions of ESWL and URS, respectively, was 1.4 ± 0.7 and 0.8 ± 0.9 in group 1 and 4.0 ± 2.0 and 1.5 ± 1.3 in group 2. The mean times to achieve these rates were 3.2 ± 1.7 months and 5.6 ± 2.3 months for groups 1 and 2, respectively. One patient in group 2 was treated with only three sessions of ESWL. Renal colic was observed in only five patients (17.9%).ConclusionsMiniJFil® stenting is safe and may be an alternative for the treatment of kidney stones during minimally invasive procedures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.